753440-87-8

Usage

Uses

Due to the limited information available on Spiro[piperidine-4,4-[4H]pyrido[2,3-d][1,3]oxazin]-2(1H)-one (9CI), it is difficult to provide a comprehensive list of its applications. However, based on its chemical structure and classification as a piperidine, it can be inferred that Spiro[piperidine-4,4-[4H]pyrido[2,3-d][1,3]oxazin]-2(1H)-one (9CI) may have potential uses in the following areas:
Used in Chemical Research:
Spiro[piperidine-4,4-[4H]pyrido[2,3-d][1,3]oxazin]-2(1H)-one (9CI) is used as a research compound for exploring its chemical properties and potential reactivity with other molecules. Its unique spiro structure and multiple reactive groups make it an interesting candidate for studying various chemical reactions and interactions.
Used in Synthesis:
In the field of organic synthesis, Spiro[piperidine-4,4-[4H]pyrido[2,3-d][1,3]oxazin]-2(1H)-one (9CI) may be used as a building block or intermediate in the synthesis of more complex molecules. Its presence in the chemical literature suggests that it could be a valuable component in the development of new compounds with specific properties or applications.

Upstream product

• 883984-95-0 7'-chloro-2'-oxo-1',2'-dihydro-1H-spiro[piperidine-4,4'-pyrido[2,3-d][1,3]oxazine]-1-benzyl carboxylate 

Downstream Products

• 885030-22-8 C₂₉H₃₂F₂N₆O₄ 
• 1354640-51-9 4-nitrophenyl 2'-oxo-1',2'-dihydrospiro[piperidine-4,4'-pyrido[2,3-d][1,3]oxazine]-1-carboxylate 

Relevant academic research and scientific papers

NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS

The invention relates to novel heterocyclic compounds of general formula (I), as well as their pharmaceutically acceptable salts, and their enantiomers. The invention also relates to the use thereof as a medicinal product, preferably in the prevention and/or treatment of inflammatory diseases with a neurogenic component or use thereof as a cosmetic. The compounds of the present invention act as antagonists of the CGRP-R receptor.

Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: Development of novel spiropiperidines

Several novel spiropiperidine-based CGRP receptor antagonists have been developed that maintain good potency and have reduced potential for metabolism.

HETEROCYCLIC BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: (where variables R2, R7, D, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of Formula I: Formula I: I and Formula II: (where variables R1, R2, R3, R4, A, B, J, Q, T, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CGRP RECEPTOR ANTAGONISTS

Compounds of Formula (I): and Formula (II): (where variables R2, R4, A, B, D, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CGRP RECEPTOR ANTAGONISTS

Compounds of Formula (I), (where variables R1, A, B, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.